Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilusAmer M. Zeidan, Matteo Della Porta, Lionel Adès et al.|Blood|2025Cited by 1
MDS-1047: RENEW Trial in Progress: A Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate Elritercept in Participants With Transfusion-Dependent Anemia and Lower-Risk Myelodysplastic NeoplasmsRami S. Komrokji, Jen L. Salstrom, María Diez‐Campelo et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0